Abstract:Background: Alzheimer’s disease (AD) as an age-related, irreversible neurodegenerative disease, characterized by cognitive dysfunction, has become progressively serious with a global rise in life expectancy. As the failure of drug elaboration, considerable research effort has been devoted to developing therapeutic strategies for treating AD. TCM is gaining attention as a potential treatment for AD. Gastrodia elata Blume, Polygala tenuifolia Willd., Cistanche deserticola Ma , Rehmannia lutinosa (Gaertn.)DC. , Acorus gramineus Aiton, and Curcuma longa L. (GPCRAC) are all well-known Chinese herbs with neuroprotective benefits and are widely used in traditional Chinese decoction for AD therapy. However, the efficacy and further mechanisms of GPCRAC extracts in AD experimental models are still unclear. The purpose of this study was to investigate the synergistic protective efficacy of GPCRAC extracts (composed of extracts from these six Chinese medicines), and the protein targets mediated by GPCRAC extracts in treating AD. Methods: Scopolamine-induced cognitive impairment mouse model was established to determine the neuroprotective effects of GPCRAC extracts in vivo , as shown by behavioral tests and cerebral cholinergic function assays. To identify the potential molecular mechanism of GPCRAC extracts against AD, label-free quantitative proteomics coupled with tandem mass spectrometry (LC-MS/MS) were performed. The integrated bioinformatics analysis was applied to screen the core differentially expressed proteins in vital canonical pathways. Critical altered proteins were validated by qPCR and Western blotting. Results: Administration of GPCRAC extracts significantly recovered scopolamine-induced cognitive impairment, as evidenced by the improved learning and memory ability, increased Ach content and ChAT activity, as well as decreased AchE activity in the hippocampus of mice. In total, 390 proteins with fold-change>1.2 or <0.83 and p < 0.05 were identified as significant differentially expressed proteins, of which 110 were significantly up-regulated and 25 were significantly down-regulated between control and model group. By mapping the significantly regulated proteins, we identified five hub proteins: PPP2CA, Gsk3β, PP3CC, PRKACA, and BCL-2 that were associated with dopaminergic synapse and apoptosis signaling pathway, respectively. Western blotting and QPCR demonstrate that the expression levels of these core proteins could be significantly improved by the administration of GPCRAC extracts. These pathways and some of the identified proteins are implicated in AD pathogenesis. Conclusion: Administration of GPCRAC extracts was effective on alleviating scopolamine-induced cognitive impairment, which might be through modulation of dopaminergic synapse and apoptosis signaling pathway. Consequently, our quantitative proteome data obtained from scopolamine-treated model mice successfully characterized AD-related biological alterations and proposed novel protein biomarkers for AD.

Neuroprotective Effects of HTR1A Antagonist WAY-100635 on Scopolamine-Induced Delirium in Rats and Underlying Molecular Mechanisms

5-HT(1A) Receptor Antagonist Improves Behavior Performance of Delirium Rats Through Inhibiting PI3K/Akt/mTOR Activation-Induced NLRP3 Activity

Changes of different monoamine transmitters in cerebrospinal fluid of rats with scopolamine induced delirium

Scopolamine Causes Delirium-Like Brain Network Dysfunction and Reversible Cognitive Impairment Without Neuronal Loss.

Amelioration of scopolamine-induced learning and memory impairment by the TRPV4 inhibitor HC067047 in ICR mice

Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice

Scopolamine promotes neuroinflammation and delirium-like neuropsychiatric disorder in mice

WY14643 Attenuates the Scopolamine-Induced Memory Impairments in Mice.

Traditional Chinese Medicine Shenmayizhi Decoction Ameliorates Memory and Cognitive Impairment Induced by Scopolamine Via Preventing Hippocampal Cholinergic Dysfunction in Rats

The Requirement of L-Type Voltage-Dependent Calcium Channel (L-VDCC) in the Rapid-Acting Antidepressant-Like Effects of Scopolamine in Mice

Micro-infusion of 5-HT1a receptor antagonists into the ventral subiculum ameliorate MK-801 induced schizophrenia-like behavior in rats

The Selective 5-HT1A Receptor Antagonist WAY-100635 Inhibits Neuronal Activity of the Ventromedial Prefrontal Cortex in a Rodent Model of Parkinson’s Disease

Intra-Prefrontal S-Oh-Dpat And M100907 Improve Visuospatial Attention And Decrease Impulsivity On The Five-Choice Serial Reaction Time Task In Rats

Scopolamine-induced Delirium Promotes Neuroinflammation and Neuropsychiatric Disorder in Mice

Chinese Herbal Extracts Exert Neuroprotective Effect in Alzheimer’s Disease Mouse Through the Dopaminergic Synapse/Apoptosis Signaling Pathway

(m) RVD-hemopressin (α) Ameliorated Oxidative Stress, Apoptosis and Damage to the BDNF/TrkB/Akt Pathway Induced by Scopolamine in HT22 Cells

Protective Effect of Recombinant Ganoderma Lucidum Immunomodulatory Protein (rLZ-8) Against Scopolamine-Induced Alzheimer's Disease in Rats

Involvement of serotonin neurotransmission in hippocampal neurogenesis and behavioral responses in a rat model of post-stroke depression

Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells.

The Selective 5-HT1A Receptor Antagonist WAY-100635 Increases Neuronal Activity of the Basolateral Nucleus of the Amygdala in 6-Hydroxydopamine-lesioned Rats

Effect of Flavonoids in Scutellariae Radix on Depression-Like Behavior and Brain Rewards: Possible in Dopamine System